{"title":"Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I11.1840","DOIUrl":null,"url":null,"abstract":"Pernix Therapeutics, a US-based speciality pharmaceutical company primarily focused on the paediatric market, has agreed to acquire the privately held generics developer Cypress Pharmaceutical and its branded pharmaceuticals subsidiary Hawthorn Pharmaceuticals for up to US$101 M in cash and stock. Cypress and Hawthorn are together expected to generate revenues of approximately US$50 M in 2012. The acquisition is Pernix’s second of 2012 after its July purchase of Great Southern Laboratories, a contract manufacturer of OTC and prescription products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I11.1840","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Pernix Therapeutics, a US-based speciality pharmaceutical company primarily focused on the paediatric market, has agreed to acquire the privately held generics developer Cypress Pharmaceutical and its branded pharmaceuticals subsidiary Hawthorn Pharmaceuticals for up to US$101 M in cash and stock. Cypress and Hawthorn are together expected to generate revenues of approximately US$50 M in 2012. The acquisition is Pernix’s second of 2012 after its July purchase of Great Southern Laboratories, a contract manufacturer of OTC and prescription products.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
